A partnership to improve treatments for cancer patients

For the past decade WEHI’s cancer research programs have been generously supported by the Australian Cancer Research Foundation (ACRF).

The ACRF has contributed almost $6 million to the institute’s cancer research. This is assisting our researchers to unravel the big questions in cancer research, by providing new insights into how cancer develops, and how it can be more effectively treated.

The most recent grants from the ACRF to the institute have been:

  • $2.5 million in 2015 to support the establishment of the ACRF Breakthrough Technologies Laboratory, a facility to enhance and accelerate research into many of Australia’s most common, and most deadly, cancers.
  • $2 million in 2012 to enable the fit-out of new cancer laboratories in WEHI’s ACRF Stem Cells and Cancer and ACRF Chemical Biology divisions, providing an important boost to the institute’s cancer research programs.

Better outcomes for people with cancer

WEHI director, Professor Doug Hilton, said the support of the ACRF was crucial in providing Australian cancer researchers with access to new, state-of-the-art research facilities.

“Support from the Australian Cancer Research Foundation has driven many important advances in understanding and treating cancer. In the long term, our partnership with ACRF will result in better outcomes for the 125,000 Australians diagnosed with cancer every year.”
– Professor Doug Hilton, WEHI Director

A commitment to conquering cancer

Australian Cancer Research Foundation logoChairman of the ACRF Board said Australia was at the forefront of cancer research globally.

“We’re proud to support WEHI in their investigations to better understand cellular errors in cancer and develop new treatments. This fantastic research team is forging a new path towards solving the tragedy of cancer.”
– Mr Tom Dery AO

Ways you can support WEHI

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Autumn 2024
View the current issue